TY - JOUR
T1 - A measuring method for occupancy of immune checkpoint inhibitors in the cell surface
AU - Yanagihara, Toyoshi
AU - Tanaka, Kentaro
AU - Matsumoto, Koichiro
N1 - Funding Information:
This research was supported by Daiwa Securities Health Foundation ( 2809 to TY) and the QR Program of Kyushu University ( 28332 to TY).
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/6/18
Y1 - 2020/6/18
N2 - Monoclonal antibodies, including immune-checkpoint inhibitors, are becoming popular in treatments of many cancers and connective tissue diseases. However, little is known about how long the antibodies combine with antigens on targeted cells or how this duration of binding associates with therapeutic efficacy or potential adverse events. Here, we show the principle and the results of a feasible method for measuring the antibodies’ occupancy on the targeted cells using two different detecting antibodies in conjunction with different fluorochromes. Nivolumab occupancy was measured using two detecting antibodies, MIH4 and EH12.2, which are commercially available in vitro (programmed cell death-1 [PD-1] expressing the cell line MIT9 and human T cells) and in T cells from patients treated with nivolumab. Our method has potential for use as a simple and feasible monitoring system in the clinical setting.
AB - Monoclonal antibodies, including immune-checkpoint inhibitors, are becoming popular in treatments of many cancers and connective tissue diseases. However, little is known about how long the antibodies combine with antigens on targeted cells or how this duration of binding associates with therapeutic efficacy or potential adverse events. Here, we show the principle and the results of a feasible method for measuring the antibodies’ occupancy on the targeted cells using two different detecting antibodies in conjunction with different fluorochromes. Nivolumab occupancy was measured using two detecting antibodies, MIH4 and EH12.2, which are commercially available in vitro (programmed cell death-1 [PD-1] expressing the cell line MIT9 and human T cells) and in T cells from patients treated with nivolumab. Our method has potential for use as a simple and feasible monitoring system in the clinical setting.
UR - http://www.scopus.com/inward/record.url?scp=85083880933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083880933&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2020.04.122
DO - 10.1016/j.bbrc.2020.04.122
M3 - Article
C2 - 32446369
AN - SCOPUS:85083880933
SN - 0006-291X
VL - 527
SP - 213
EP - 217
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -
